Approval · Notice of Compliance 21053 · 2018
PRAXBIND: Notice of Compliance 21053
Issued June 28, 2018
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21053
- Date
- June 28, 2018
- Company
- Boehringer Ingelheim (Canada) Ltd.Burlington, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfillment of commitment a of the letter of undertaking dated march 28, 2016 issued under nds conrtol no. 128503
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PRAXBIND | Not yet assigned | — |
Medicinal ingredients
- IDARUCIZUMAB 2,500 MG per VIAL